头孢哌酮舒巴坦联合莫西沙星治疗AECOPD合并肺炎克雷伯菌肺炎的疗效观察

目的：观察头孢哌酮舒巴坦联合莫西沙星治疗慢性阻塞性肺疾病急性加重（AECOPD）合并肺炎克雷伯杆菌肺炎患者的疗效。方法按标准纳入57例患者，分别采用头孢哌酮舒巴坦联合莫西沙星治疗（观察组）和头孢哌酮舒巴坦单药治疗（对照组）。比较两组的临床疗效。结果观察组的患者体温恢复正常时间、白细胞计数恢复正常时间、肺部湿啰音消失时间均明显短于对照组，差异均有统计学意义（P均＜0.05）。观察组治疗有效率（90.0%）和细菌清除率（86.7%）均显著高于对照组（77.8%和74.1%），差异均有统计学意义（P均＜0.05）；两组均无严重不良事件发生。结论头孢哌酮舒巴坦联合莫西沙星可有效治疗AECOPD合并肺炎克雷伯杆菌肺炎。

Clinical study of the combination therapy in patients with AECOPD

Objective To compare the efficacy and safety of different antibiotic combination strategies in the treatment of AECOPD patients. Methods 86 AECOPD patients were randomly divided into two groups. The observation group（n=30）was given cefoperazone/sulbactam plus moxifloxacin treatment, and the control group（n=27）was treated with cefoperazone/sulbactam. Results The total effective rate was 90.0%and the bacterial clearance was 86.7%in the observation group, which were higher than those in the control group（77.8%and 74.1%respectively）. The differences in time of body temperature returned to normal , white blood cell count back to normal, pulmonary time of rales disappeared and rates of adverse event between the two groups showed no statistical significance（P〉0.05）. Conclusion Cefoperazone/sulbactam plus moxifloxacin is effective in the treatment of lower respiratory tract klebsiella pneumonia infection of AECOPD.